This National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) grant is offering funding to continue the Drug-Induced Liver Injury Network (DILIN) Clinical Centers. These centers are essential components for identifying, enrolling, and clinically characterizing patients eligible for DILIN. Drug-induced liver injury (DILI) is a challenging liver disease, often difficult to diagnose and manage, with various drugs and supplements implicated in its cause. Over the past 19 years, DILIN has become the primary global source for information and progress in understanding DILI’s burden, clinical presentation, and outcomes. The ultimate aim of this grant is to further elucidate the clinical and pathophysiologic features of DILI, leading to improved understanding, treatment, and prevention, thereby decreasing the burden of this disease.
Opportunity ID: 343218
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | RFA-DK-22-013 |
| Funding Opportunity Title: | Drug Induced Liver Injury Network (DILIN) Clinical Centers (U01 – Clinical Trial Optional) |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Cooperative Agreement |
| Category of Funding Activity: | Food and Nutrition Health |
| Category Explanation: | – |
| Expected Number of Awards: | – |
| Assistance Listings: | 93.847 — Diabetes, Digestive, and Kidney Diseases Extramural Research |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 1 |
| Posted Date: | Aug 24, 2022 |
| Last Updated Date: | Aug 24, 2022 |
| Original Closing Date for Applications: | Oct 27, 2022 |
| Current Closing Date for Applications: | Oct 27, 2022 |
| Archive Date: | Dec 02, 2022 |
| Estimated Total Program Funding: | – |
| Award Ceiling: | $1,800,000 |
| Award Floor: | – |
Eligibility
| Eligible Applicants: | Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education City or township governments Public and State controlled institutions of higher education Private institutions of higher education For profit organizations other than small businesses Native American tribal governments (Federally recognized) Public housing authorities/Indian housing authorities Special district governments Independent school districts Others (see text field entitled “Additional Information on Eligibility” for clarification) Small businesses County governments State governments Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Native American tribal organizations (other than Federally recognized tribal governments) |
| Additional Information on Eligibility: | Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are not allowed. |
Additional Information
| Agency Name: | National Institutes of Health |
| Description: | The purpose of this Funding Opportunity Announcement is to invite applicationsfor for clinical centers for the continuation of the Drug-Induced Liver Injury Network (DILIN). The DILIN Clinical Centers are the components of the Network to identify, enroll and clinically characterize patients eligible for the DILIN. The companion RFA (RFA- DK-22-508) seeks to continue the Data Coordinating Center for DILIN. Drug-induced liver injury (DILI) is one of the more challenging forms of liver disease; both in diagnosis and management. Several hundred drugs, dietary and herbal supplements have been implicated in causing liver injury. Their clinical presentation can be highly variable and mimic almost any form of liver disease. Over the last 19 years, the DILIN throughout its publications has become the major source of information and progress in understanding the burden of drug-induced liver injury for clinicians, hepatologists, researchers, and the public at large in the US and Worldwide. The Network has made major advances in the understanding of the clinical presentation and outcomes of liver injury due to drugs as well as herbal and dietary supplements (HDS). These advances have led to exploratory inroads on the pathogenesis of DILI. DILIN remains the only structured, systematic and prospective effort in the United States and world-wide to characterize drug and HDS induced liver injury. The ultimate aims of DILIN are to elucidate the clinical and pathophysiologic features of DILI so as to allow inroads into its understanding, treatment and prevention, thus decreasing the burden of this disease. |
| Link to Additional Information: | https://grants.nih.gov/grants/guide/rfa-files/RFA-DK-22-013.html |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
NIH Grants Information
grantsinfo@nih.gov Email:grantsinfo@nih.gov |
Version History
| Version | Modification Description | Updated Date |
|---|---|---|
Related Documents
There are no related documents on this grant.
Packages
| Agency Contact Information: | NIH Grants Information grantsinfo@nih.gov Email: grantsinfo@nih.gov |
| Who Can Apply: | Organization Applicants |
| Assistance Listing Number | Competition ID | Competition Title | Opportunity Package ID | Opening Date | Closing Date | Actions |
|---|---|---|---|---|---|---|
| FORMS-G | Use for due dates on or after January 25, 2022 | PKG00276541 | Sep 27, 2022 | Oct 27, 2022 | View |
Package 1
Mandatory forms
343218 RR_SF424_5_0-5.0.pdf
343218 PHS398_CoverPageSupplement_5_0-5.0.pdf
343218 RR_OtherProjectInfo_1_4-1.4.pdf
343218 PerformanceSite_4_0-4.0.pdf
343218 RR_KeyPersonExpanded_4_0-4.0.pdf
343218 PHS398_ResearchPlan_4_0-4.0.pdf
343218 PHSHumanSubjectsAndClinicalTrialsInfo_3_0-3.0.pdf
Optional forms
343218 RR_Budget_3_0-3.0.pdf
343218 RR_SubawardBudget30_3_0-3.0.pdf
343218 PHS398_ModularBudget_1_2-1.2.pdf
343218 PHS_AssignmentRequestForm_3_0-3.0.pdf
Share This Post, Choose Your Platform!
About the Author: osnqt
